Back

Do we need new randomised trials to assess the role of the defibrillator? - the PROFID EHRA trial

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: The role of the primary prevention defibrillator after myocardial infarction in the era of modern heart failure therapy: the PROFID project Implantable Cardioverter-Defibrillator (ICD) Open Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Nikolaos Dagres

Charité - University Medicine Berlin, Berlin (Germany)

2 More presentations in this session

Presentation thumbnail
Risk of sudden cardiac death after myocardial infarction under contemporary heart failure treatment
Professor M. Taborsky (Usti Nad Labem, CZ)
Slides Video
Presentation thumbnail
Prediction of risk for sudden cardiac death beyond the ejection fraction
Professor V. Kutyifa (Rochester, US)
Slides Video

Access the full session

Session thumbnail
The role of the primary prevention defibrillator after myocardial infarction in the era of modern heart failure therapy: the PROFID project
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Update on sudden cardiac death: current landscape and challenges in sudden cardiac death prevention
thumbnail
Congress Presentation
Generating evidence for future guidelines for primary prevention ICD implantation in ischemic cardiomyopathy : the PROFID EHRA trial
thumbnail
Congress Presentation
Risk prediction for sudden cardiac death. Insights from PROFID and other projects

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources